Cantor Fitzgerald Issues Negative Outlook for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Apellis Pharmaceuticals in a research note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will earn ($2.38) per share for the year, down from their prior estimate of ($0.94). Cantor Fitzgerald currently has a “Overweight” rating and a $44.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The firm had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.54) earnings per share.

Several other equities research analysts have also issued reports on APLS. Wedbush dropped their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Robert W. Baird cut their price objective on Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating for the company in a report on Thursday, May 8th. The Goldman Sachs Group decreased their price objective on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Finally, Needham & Company LLC lowered their target price on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Nine investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.37.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS opened at $17.28 on Monday. Apellis Pharmaceuticals has a 52-week low of $16.65 and a 52-week high of $43.99. The stock has a fifty day moving average of $20.99 and a 200 day moving average of $26.99. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -8.51 and a beta of 0.73.

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its position in Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after purchasing an additional 758 shares during the period. Assetmark Inc. raised its stake in Apellis Pharmaceuticals by 3,938.7% during the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock valued at $27,000 after buying an additional 1,221 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after buying an additional 918 shares during the period. GF Fund Management CO. LTD. boosted its stake in shares of Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock worth $70,000 after buying an additional 573 shares during the last quarter. Finally, US Bancorp DE grew its holdings in shares of Apellis Pharmaceuticals by 70.0% in the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock worth $103,000 after acquiring an additional 1,327 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares of the company’s stock, valued at approximately $3,482,123. The trade was a 3.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.50% of the stock is owned by company insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).